CONTRIBUTORS

HELEN M. ARIZPE The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

ANN M. ARVIN Infectious Disease Division, Department of Pediatrics and Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California; USA

ANGELOS ATHANASSOPOULOS NCI-Frederick Cancer Research Facility, BRI­Basic Research Program, P.O BOX B, Frederick, Maryland; USA

SUSAN BAKER National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado; USA

WILLIAM BENNETT Harvard School of Public Health and Harvard Medical School, Boston, Massachusetts; USA

FRANCOIS BOUCHER Infectious Disease Division, Department of Pediatrics and Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California; USA

CHRISTOS CLADARAS NCI-Frederick Cancer Research Facility, BRI-Basic Re­search Program, P.O BOX B, Frederick, Maryland; USA

NORA M. CRAPMAN The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

PAMELA S. DIAZ Infectious Disease Division, Department of Pediatrics and Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California; USA

BARBARA K. FELBER NCI-Frederick Cancer Research Facility, BRI-Basic Re­search Program, P.O BOX B, Frederick, Maryland; USA

BONINO FERRUCCIO Division of Gastroenterology, San Giovanni Battista "Molinette" Hospital Corso Bramante 88, 10126, Torino, Italy

OLIVERI FILIPPO Division of Gastroenterology, San Giovanni Battista "Molinette" Hospital Corso Bramante 88, 10126, Torino, Italy

PHYLLIS R. FLOMENBERG Department of Medicine, Veterans Administration Medical Center, lst Avenue at E. 24th Street, New York, NY; USA

ROSINA FLORIANO Division of Gastroenterology, San Giovanni Battista "Molinette" Hospital Corso Bramante 88, 10126, Torino, Italy

DANA GALLO California Department of Health Service, Division of Lab­oratories, Viral and Rickettsial Disease Laboratory, 2151 Berkeley Way Berkeley, CA 94704; USA

315

CHARLES J. GAUNTT The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

ELMER K. GODENY The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

JONATHAN w. M. GOLD Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021; USA

VICTOR DE GRUTTOLA Harvard School of Public Health and Harvard Medical School, Boston, Massachusetts; USA

MARGARITA HADZOPOULOU-CLADARAS NCI-Frederick Cancer Research Facility, BRI-Basic Research Program, P.O BOX B, Frederick, Maryland; USA

PAUL A. HENSLEIGH Infectious Disease Division, Department of Pediatrics and Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California; USA

MARSHALL S. HORWITZ Departments of Microbiology-Immunology, Cell Biology and Pediatrics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York; USA

JAMES F. JONES National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado; USA

C. WILLIAM LUTTON The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

STEPHEN MARTIN Department of Microbiology, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996-0845; USA

JOSEPH W. McCRAY Sandoz-Forschungsinstitut GmbH, Brunnerstrasse 59 A-1235 Vienna, Austria

JOSEPH D. MOSCA Henry M. Jackson Foundation, Rockville, MD 20850; and the Department of Immunology and Infectious Diseases, The Johns Hopkins University School of Public Health, Baltimore, MD 21205; USA

GEORGE N. PAVLAKIS NCI-Frederick Cancer Research Facility, BRI-Basic Research Program, P.O BOX B, Frederick, Maryland; USA

CHARLES G. PROBER Infectious Disease Division, Department of Pediatrics and Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California; USA

GEORGE E. REVTYAK The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

BRUNETTO MAURIZIA ROSSANA Division of Gastroenterology, San Giovanni Battista "Molinette" Hospital Corso Bramante 88, 10126, Torino, Italy

BARRY T. ROUSE Department of Microbiology, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996-0845; USA

MARIUS M. ROZEK The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

EVAN STEINBERG Regional Virology Laboratory and Department of Pedi­atrics, Southern California Kaiser Permanente, North Hollywood and Los Angeles, California; USA

316

JOANNE STREIB National Jewish Center for Inununology and Respiratory Medicine, Denver, Colorado; USA

WAYNE M. SULLENDER, Infectious Disease Division, iatrics and Department of Obstetrics and Gynecology, School of Medicine, Stanford, California; USA

Department of Ped­Stanford University

STEVEN M. TRACY The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

ANTHONY J. VALENTE The University of Texas Health Science Center of San Antonio, San Antonio, Texas 78284-7758; USA

ANN L. WARFORD Regional Virology Laboratory and Department of Pedi­atrics, Southern California Kaiser Permanente, North Hollywood and Los Angeles, California; USA

GUDRUN WERNER Sandoz-Forschungsinstitut GmbH, Brunnerstrasse 59 A-1235 Vienna, Austria

CONNIE M. WRIGHT NCI-Frederick Cancer Research Facility, BRI-Basic Re­search Program, P.O BOX B, Frederick, Maryland; USA

317

AUTHOR INDEX

Aarnaes, S.L., 275 Abbo, H., 280 Agah, R., 313 Akita, R., 294 Allen, M., 280 Al-Sumidaie, A.M., 298 Andresen, D., 274 Arizpe, H.M., 161 Arvin, A.M., 41 Ascher, M.S., 290 Ashley, R., 280 Athanassopoulos, A., 151 August, M.J., 286

Bahn, M., 287 Baker, S., 87 Banach, M., 270 Barlow, W.E., 307 Barton, W.E., 276 Bednarik, D.P., 304 Beneson, A.S., 290 Bennett, W., 121 Bin, X., 310 Bishop, P., 311 Bolivar, S., 277 Boucher, F., 41 Brady, M.T., 281, 299 Brandis, J.W., 291, 292, 293, 294,

295 Brewer, J.M., 276 Brewer, P.P. 276 Bromberg, K., 286 Buffa, L., 313 Butler, G., 289

Carpenter, R.H., 303 Cepica, A., 312 Chao, L.A., 309 Chetty, C., 296 Christian, C.M., 293 Churchill, F.E., 301 Cladaras, C., 151 Coates, S.R., 291, 292, 293, 295,

309 Cozza, C., 280 Crapman, N.M., 161 Cuartas, J.F., 281, 299 Curtis, S.E., 278

Dakos, J., 277 Darougar, S., 285 de la Maza, L.M., 275 Diaz, P.S., 41 Dick, D., 289 DiTullio, D., 292 Drew, W.L., 282

Elwell, R., 290 Espy, M.J., 288

Farr, R.W., 311 Felber, B.K., 151 Ferrer, M., 292, 294 Ferruccio, B., 73 Filippo, 0., 73 Flomenberg, P.R., 183 Floriano, R., 73 Flowers, T.S., 296 Forghani, B., 283 Fraser, C., 271 Fraser, R, 271 Furukawa, T., 310

Gallo, D., 23 Gauntt, C.J., 161 Gaynor, R., 311 Girolami, P.C. de, 277 Gleaves, C.A., 270, 272, 278 Godeny, E.K., 161 Gold, J.W.M., 105 Goldstein, G., 305 Goodreau, S., 284 Gruttola, V. de, 121

Hadzopoulou-Cladaras, M., 151 Hand, R.E., 308 Harris, A.J., 292, 294 Hay-Kaufman, M., 271 Heberling, R.L., 269 Hensleigh, P.A., 41 Hills, R.A., 289 Hofherr, L.K., 290 Horwitz, M.S., 183 Hursh, D.A., 272 Hurst, J.W., 283

319

Ishida, K., 310

Jespersen, D.J., 288 Jones, J.F., 87 Judson, B., 270

Kalter, S.S., 269 Kamibayashi, R., 271 Kawula, M., 271 Kay, J.W.D., 296 Keitelman, E.L., 294, 295 Kennedy, D.A., 289 Kenyon, B.R., 273 Knapp, s., 295

Langton, B.C., 295 Larocca, D., 309 Lee, C.F., 278 Leombruno, D., 286 Liu, H.-L., 294, 295 Lutton, C.W., 161

Martin, S., 239 Mazumder, A., 313 McAnalley, B.H., 303 McCray, J.W., 213 McDaniel, H.R., 303 McGuigan, L.J.B., 307 McKendall, R.R., 297 Merrill, L., 277 Meyers, J.D., 272, 278 Miner, R.C., 282 Monette, M.T., 289 Mosca, J.D., 135, 304 Munden, F.K., 276 Murayama, T., 310

Neff-Smith, M., 301, 302 Northing, J.W., 296

Overall, J.C., 273

Parkes, D., 291 Pavlakis, G.N., 151 Paya, C.V., 279 Peddecord, K.M., 290 Peterson, E.M., 275 Pierik, L.T., 286 Pitha, P.M., 304 Prober, C.G., 41 Proffitt, M.R., 287 Pulliam, L., 300 Pulse, T., 303

320

Rabe1la, N., 282 Raj, N.B.K., 304 Railing, G., 312 Ralston, J.S., 295 Revtyak, G.E., 161 Rice, R.J., 301, 302 Roberto, A., 287 Rossana, B.M., 73 Rouse, B.T., 239 Rozek, M.M., 161

Salmon, v.c., 273 Schiff, J., 277 Scruggs, P.O., 296 Sheldon, E.L. 274 Siddiqui, A., 311 Siegel, c., 284 Simpson, P., 300 Sliwkowski, M.X., 292, 294, 295 Smith, C.M., 291, 292, 293,

294, 295, 309 Smith, T.F., 279, 288, 306 Steinberg, E., 1 Streib, J., 87 Sullender, W.M., 41

Taggart, E.W., 273 Tan, P.L., 296 Tang, N., 300 Telenti, A., 306 Teramoto, Y.A., 294 Toth, T.E., 308 Tracy, S.M., 161 Tran, K. V., 295 Trousdale, M.D., 307 Twomey, P.E., 313

Valente, A.J., 161

Wallingford, S.A., 294, 295 Walpita, P., 285 Warford, A.L., 1 Wendt, S.F., 272 Werner, G., 213 Wold, A.D., 279 Woo, w., 297 Woodrow, J.C., 298 Wright, C.M., 151 Wright, M., 309

Yason, c., 312 Yen-Lieberman, B., 287 Yu, G.-J., 283

SUBJECT INDEX

ACE-M, see Acemannan Acemannan, 303 Acquired immunodeficiency

syndrome, see AIDS Actinomycin D, 139, 140, 243-245 Activator protein, viral, 151 Acyclovir, 101-103, 306 Adenoclone antibody test, 296 Adenovirus, 182-212, 275, 285-286

adenoclone antibody test, 286 and AIDS, 186, 210 antibody, monoclonal, 286 in blood lymphocyte, peri-

pheral, 188 and cell

attachment, 187 cytopathogenic effect, 286 transformation by, 199, 200 in chicken, 202 classification of human,

184 cycle, infectious, 187-188 deoxyribonucleic acid, 183,

184 polymerase, 188, 212

DNA, see deoxyribonucleic acid E3 (early transcription

region), 183-184 endocytosis, receptor-medi-

ated, 187 enzyme immunoassay (EIA) , 286 epidemiology, 184-186 in eye, detection of, 285 gene, 184

product, 183-212 glycoprotein E3, 193-195

and MHC-binding, 193, 197 hemagglutination, 184 illness due to, 185 immune

mechanisms, 183-212 response, 189-200

immunofluorescence, 285-286 infection

latent, 183, 188-189 persistent, 183, 208-209

latency, see infection in liver transplant patient,

186

Adenovirus (continued) in lymphocyte, peripheral, of

blood, 188 and malignancy, 188-189 map, genomic, 187 microtubule, 187 in monkey kidney cells for

vaccine, 193 in mouse, 209 open reading frame, 184 pathogenesis in animals, 183 persistence, 208-209

in lymphocyte, 211 in tonsil, 211 in urinary tract, 211

and pneumonia by, 193-212 protein

nef, 154, 155 rev, 154

replication early, 187-188 late, 187

in rodent models, 200-202 serotypes, 184, 195-198 "smudge" cell, 188 specimen sources, 286 structure, 186 transcription region E3, 193-

195 transformation in tissue

culture, 184-185 in transplant patient, hepatic,

186 and tumor in animal, 184 vaccine from monkey kidney

cells, 193 African green monkey

and T-cell lymphotropic virus, 23

Agretope, 258 AIDS, 105, 106, 110, 121-134

and activity, sexual, 121-124

and adenovirus, 186, 210 in B-cell defect, 106-107 in bisexuals, 129-130 via blood transfusion, 126,

127, 132, 133

321

AIDS (continued) community assessment survey

model, 302 complications, 107 dementia complex, 113 encephalopathy, subacute,

113 epidemic, 121-134

curve of past growth, 122 doubling time of cases, 122 information

analysis, 122-129 ideology, 129-131

model for transmission, 122, 302

and practices, sexual, 121

statistics, 121, 134 genesis model of ethane­

graphic community, 302 in hemophiliacs, 127-128 and hepatitis B virus,

125, 132, 311 in heterosexuals, 128-129 and HIV, see Immunodefi­

ciency virus, human in homosexuals, 129-130,

139 and HTLV-I, see T-cell lympho­

tropic virus, type I and immunodeficiency

virus, human, see HIV immunosuppression, 109 infections in, 110-114

risk after, 127-128 and latency of virus, 125

after blood transfusion, 126

models for, 122, 302 morbidity of the at risk pop-

ulation, 302 and practices, sexual, 123-124 and prevalence of virus, 125 and promiscuity, 123 risk after infection, 127-128 susceptibility to, 134 and T-cell

defect, 106-107 and microorganisms, infec­

tious, 107 lymphotropic virus, see T­

cell lymphotropic virus therapy

cost, 106 drugs, 106

via transfusion, see blood transfusion

transmission, 122-124 see Immunodeficiency virus

T-cell lymphotropic virus, type I

Alkaline phosphatase, 152, 283 Amino transferase, 305 Amphotericin B, 112 Anemia, hemolytic, 289

322

crisis, aplastic, 289 and parvovirus B19, 289

Antibody antipeptide, viral, 215-224 antireceptor, 215 Canyon hypothesis, see

Canyon detection, rapid, 269 Fe receptor, 192 fluorescent, 4, 6, 9, 13, 16,

271 see Immunofluores­cence

heterophile 284 and infectious mononucleo-

sis, 284 monoclonal, 277, 300 neutralizing, 189 viral, 269 and virus resistance, 214

Antipeptide antibody, 215-224, 237, 238

specificity, 219-222 Antireceptor antibody, 215 Arachidonic acid, 172-175 Arenavirus, 255 Argon ion laser, 308 Arthritis, rheumatoid, 97, 298

and retrovirus in monocyte, 298

Asthma and rhinovirus, 213 ATL, see T-cell leukemia, adult Autoimmunity, 161, 163, 167 5-Azacytidine, 137, 138, 148, 298 Azathioprine, 81 Azidothymidine (AZT), 106 AZT, see Azidothymidine

Bacillus Calmette-Guerin T-cell stimulator, 254

Bacteriophage T~, 283 polymerase, 169 RNA, 169

B-cell, 226, 227, 231, 257 defect, 106 and infection, bacterial, 110 line, 276 and lymphoma, 110 mutation, somatic, 227 tumor and Epstein-Barr virus

102-103 BCG, see Bacillus Calmette-Guerin BHV-1, see Herpes virus-1, bovine BIOLF-70, 164 Blood, whole

donor, 299 and dot-immunobinding assay,

269 transfusion and AIDS, 25, 126,

127, 132, 133 Bone marrow, 149

cell, 313 transplantation, 313

and cytomegalovirus, 313 5-Bromo-4-chloro-3-indoyl phos­

phate, 283 Bronchitis, chronic

and rhinovirus, 213

Buffalo green monkey kidney cell (BGMK), 305

Burkitt's lymphoma, 88, 101, 103

Calcification, dystrophic in myocarditis, 164

Campylobacter jejuni, 114 Canyon hypothesis, 214-219, 223-

224 E-Caproylamidobiotin-N-hydroxy­

succinimide ester, 283 Caque strain of varicella-zoster

virus, 283 Carcinoma

hepatocellular, 80 nasopharyngeal, 95

CAT, see Chloramphenicol acetyl­transferase gene

Cell line A549, 274 B-cell, 94-95, 103, 226

see B-cell B95-8 (marmoset), 91, 93-96 C57BL/6, 191 CHO, 309 cord blood, 90, 93-94 cos, 309 dendritic, 226 Daudi, 276 episomal, 92, 94, 98, 101 fixation, 270 fluorescence, intensity of,

270 G418, 137 Get, 311 glioblastoma, 276 hairy leukemia, 26, 30 HeLa, 142-145 HEp, 287 HepG-2, 311 herpes simplex virus infected,

270 killer cell, natural, 104 L, 244, 245, 248 leukemia, hairy, 26, 30 linear, 92, 101 LNHIV-CAT, 137 LNHTL-1-lCAT, 137 LTK, 136, 141-144 lymphoblastoid, 88-93, 97 MG63, 137 Molt-4, 276 monocyte, 226 monolayer in shell vial, 270 MRC-5, 270, 271, 274-278, 287 NK, 104 see Killer cell p3HR-l, 90, 91, 95, 96 polyclonal, 92 PRK, 274 Raji, 90-92 Ramos, 276 RPMI-8226, 276 in shell vial as monolayer,

270 SLB-1, 295 T-cell, 226 in tube culture, 270 VERO, 138, 144, 241

Cell line (continued) VNHIV-CAT, 137, 139 VNHTLV-I-CAT, 137

Cell lysis mediated by cell, 189 complement, 189

Centrifugation culture, 274, 278, 287, 288

Cesarean delivery, 2, 4, 5, 7 Chancroid, 301 Chemotactin, 243 Chicken embryo lethal orphan

virus (CELO), 202 Chicken pox, 68 Chimpanzee and rhinovirus,

human, 230 Chinese hamster, 309 Chlamydia, 199 Chloramphenicol, acetyltransfer­

ase gene, bacterial (CAT) 135-140, 144, 152, 155-157, 311

Choriomeningitis lymphocytic virus (LCMV), 192, 240, 255, 258, 259

Chromatography methods, 172-173 Chronic fatigue syndrome, see

Fatigue Cirrhosis, hepatic, 78, 79, 80,

85 Cold, common

and rhinovirus, 213 burden, economic, 213

Common cold, see Cold, common Complement fixation, 269 Corticosteroid, 163 Coxsackie virus, 286

and myocarditis in mouse, 161-182

type B, 191 Cryptococcus neoformans, 112 Crystallography of picornavirus,

214 CFS, see Fatigue, chronic Cucumber mosaic virus, 74 Cycloheximide, 135-140, 245 Cyclosphosphamide, 163, 256 Cyclosporin A, 88, 163, 191 Cystitis, acute, hemorrhagic

and adenovirus, 185 Cytokine, 256

TNF, 192 Cytolysis, 190 Cytomegalovirus, 112, 136, 146,

245, 249, 300, 306, 310, 313

antibody, 281 monoclonal, 277, 278, 306

antigen, early, 277 in blood leukocyte, 279 centrifugation culture, 278,

279 in children, immunocom-

promised, 281 cytopathogenic effect, 277 detection, 279 disease by, 111-112 DNA, 300 in heart muscle cell, human,300

323

Cytomegalovirus (continued) immunofluorescence test,

indirect, 277 immunoglobulin

IgG, 310 IgM, 280, 282

in leukocyte of blood, 279 in mouse, 313

bone marrow transplanta­tion, 313

in organ transplant patient, 300

in pneumonia, 111-112 protein 65K, 310 separation methods, 279 shell vial

assay, 306 culture, 277-279

strain AD169, 306 Towne, 300

in transplant patient cardiac, 280 organ, 300

in transplantation of bone marrow, murine, 313

Cytotoxicity, cell-mediated, 98 see T-cell, cytotoxic

Dapsone, 111 Dementia complex in AIDS, 113 Dengue fever virus, 192 Dexamethasone in medium, 10-15,

17 Dextran sulfate, 303 DFA, monoclonal, test, 5-7 Diabetes type ,I, 191 6-Diaxo-5-oxo-L-norleucine, 305 Diclofenac, 307 (9-(1,3-dihydroxy-2-propoxy-

methyl) guanidine, see Gancyclo­vir

Dimethyl sulfoxide, 10 DNA, 135, 137, 283, 308

polymerase, 38, 188 DON, see 6-Diaxo-5-oxo-L­

norleucine Dot-immunobinding assay, 269 Drug abuser, intravenous, 32, 34,

38, 302

Echovirus, 286 type-9, 218

Ectromelia poxvirus, 255 Eicosanoid, 172, 173 ELISA, 8, 9, 43-46, 53, 156, 215,

219-222, 228, 269, 274, 281, 291-296, 312

Encephalitis by herpes simplex virus type-2, 51

Encephalopathy in AIDS, 113 Endocytosis

receptor-mediated, 187 Enterovirus, 275 Enzyme immunoassay (EIA), 4,

10-13, 16, 17' 28, 29, 31, 33, 34, 273, 290

see Western blot

324

Enzyme-linked immunoabsorbent assay, see ELISA

Epitope, 42, 45, 214, 223-225, 295 Epstein-Barr virus, 87-104

antibody, heterophil, test, 284 antigen, 97

early, 284 nuclear, 284

in B-cell tumor, 101 cell culture, 89-94

transformation, 89, 90, 94-97

chronic fatigue syndrome, 87-104

described in 1988, 87 skepticism, 87

cyclosporin A, 88 cytotoxicity, cell-mediated,

98 DNA, 88-93 epidemiology, molecular, 87-

104 genome pattern, 90 hemolysis test in ox cell, 284 infection, active vs. latent,

88 leukocyte transformation by,

88 lymphocyte transformation,

74, 80 in lymphoma, 101 markers for, 284 mononucleosis, infectious, 284 monospot test, 284 ox cell hemolysin test, 284 repeat fragment, internal, 95-

96 serology, 284 syndrome

of chronic fatigue, 87-104 of mononucleosis, 284

and transformation of cell culture, 89, 90, 94-97 leukocyte, 88 lymphocyte, 74, 80

type A virus, 94, 98 B virus, 94, 98

Erythema infectiosum and parvovirus, 289

Escherichia coli, 225, 283, 291-294

Eye viruses, 285

Factor rheumatoid, 282 transactivating, viral, 244

Fansidar, 111 Fatigue, chronic, syndrome

and Epstein-Barr virus, 87-104

skepticism, 87 Fever, pharynoconjunctival

and adenovirus, 185 Fibroblast, 53, 136, 153, 277,

300 Fifth disease, see Erythema

infectiosum Flow cytometry, 308 Fluconazole, 112

Fluorescence, 270, 271, 282 see Antibody

5-Fluorocytosine, 112 Flurbiprofen, 307 Foscarnet, 112 Foot-and-mouth disease virus

215, 226, 229 Freund's adjuvant, complete 229 Fructose-6-phosphate, 305

Gancyclovir, 102, 103, 112, 306 Gastroenteritis

and adenovirus, 185 Gel particle agglutination, 29,

38 Gene

intermediate early, see IE product, viral, ~44, 245

of adenovirus, 183-212 tax, 25-26

Genesis model of ethanographic community, 302

Geysen mapping, 295 Glioblastoma, human

cell line, 276 ~-Globin gene, murine, 143 Glucosamine, 305 Glutamine, 305 Glycoprotein, 190, 197, 241, 253

inhibitor, see Tunicamycin Golgi apparatus, 251, 253 Gonorrhea, 302 Granulocyte-macrophage colony

factor, 220 Guinea pig, 60-63

Hairy cell leukemia, 26, 30 Heart muscle cell, human

and cytomegalovirus, 300 HeLa cell, 152, 154 Hemagglutination, 184

assay, indirect 281 Hemagglutinin, 241, 247, 249, 259 Hemocyanin of key hole limpet,215 Hemophilus influenzae, 110 Hepatitis, viral, 76-79

canine, 201-202 therapy, 81

Hepatitis virus, 185, 209, 231, 311

type B, 73, 125, 132 in AIDS, 125, 132 antigen

carrier, 75, 76, 80 core, 77 surface (HB5 Ag), 75, 76, 80, 201

carrier of surface antigen see antigen

core antigen, 77 gene product, 311 helper function for delta

virus, 73 see delta below

and immunodeficiency virus (HIV), 311

in lymphocyte, 86 RNA polymerase, 85

Hepatitis virus (continued) surface antigen, 75, 76,

80, 201 type delta, 73-86

antibody, 74-78 antigen, 73, 76-79 biology, 73-74 carrier, chronic, 75, 77,

79 in chimpanzee, 73 disease, 76-79 epidemiology, 75-76 and gamma-globulin, 84 pathology, 79-80 prevalence, 75-78 protein, 74 RNA, 73, 74, 78, 79, 84 therapy, 81 transmission via gamma-

globulin, 84 vaccine, 81

Hepatocyte, 79, 80 Hepatosplenomegaly, 24 Herpes

keratitis, 307 and drugs, 307

labialis, 297 and virus shedding, 297

Herpes simplex virus (HSV), 1-21, 41-71, 110, 185, 239-241, 255, 257, 259, 286, 297, 307

antibody, 275-276, 310 antigen, 244, 274, 276 bovine, 307-310 cell culture, 5-9, 11, 12, 15,

270 cell lines, 271-273 and Cesarean delivery, 2, 4-7 clearance ability, 241, 297 cytopathogenic effect, 7-16,

308 detection methods, 9, 276

from eye, 285 diagnosis, 9-15 electron microscopy, 9 in eye, 285, 307 flow cytometry, 308 fluorescence assay, indirect,

276, 285 gene

alpha, 249 immediate early (IE), 140-

145, 245 product, 139-145

genital, 1, 5, 6, 44-49, 66-67 prevalence, 66-67

glycoprotein, 41, 248 B, 241, 243 D, 241 G, 2, 43-51

identification, rapid, 271 IE (immediate early) genes,

140-145, 245 immunofluorescence method,

276, 285 immunoprecipitation, 41-42 incubation period, clinical, 4

325

Herpes simplex virus (continued) infection, opportunistic, 145

and AIDS, 145 isolation, 4-7 kidney cell of rabbit culture,

10-12 lesions listed, 6 LTR promoter sequence, 142-145 membrane enzyme immunoassay,

140 in mouse, 241

model for clearance, 297 mutant, temperature-sensitive,

140 neonatal, 1-3, 44, 48-51 nucleic acid hybridization, 9 perinatal, 1-21 prevalence in U.S.A., 1-3 proteins and immunity, 41-71 in rabbit, 10-12, 15, 20, 307 RAMP confirmation test, 271-

272 roseola, 104 shedding is symptomatic, 17,

297 shell vial culture, 270-271 source of specimens, 8 TAR region, 142 tat III region, 142-143 test, serological, 4 transactivation of HIV-1,

135-149 tube culture, 270 type-2, 43-51 type-6, 104, 276 Western blot, 42

Herpes simplex type-2 virus,43-51 antibody, 43-45 genital, 44-49 glycoprotein, 43-51

and immunity, 43-51 immunoblot, 43-44 immunity, 43-51 in pregnancy, 47-48 prevalence, 43

Histocompatibility complex major (MHC),

class I, 184, 190-198, 200, 239-242, 248, 253,-254

class II, 190, 231, 237-242, 258

HIV, see Immunodeficiency virus HSV, see Herpes simplex virus HTLV-I, see T-cell lymphotropic

virus, human, type I Hydrops fetalis

and parvovirus, 289 Hydroxyeicosatetraenoic acid, 172 Hypercalcemia, 24 Hypersensitivity, delayed, 236 Hypogammaglobulinemia, 101

Ibuprofen, 163 IE gene, 140-145, 245

product (regulatory protein), 136, 141-145

Immediate early, see IE Immune

cytolysis, see Cytolysis

326

Immune (continued) deficiency syndrome, see AIDS mechanism,· see response response, 189-200

of adenovirus gene products, 183-212 cellular, 189-190, 236 cytolysis, MHC-restricted

190-191 humoral, 189-190 and infection, viral,

189-200 local, 227-229

and rhinovirus, 227 modulation of, 192-193 pathology of, 191-200

Immunoaffinity chromatography, 53, 62

Immunoblot analysis, 43-46, 219, 220, 291-294, 297, 310

Immunodeficiency, acquired, see AIDS

Immunodeficiency virus, human type-1, 25, 105-110,

121-149, 192, 259, 301, 311

acemannan treatment, 303 activator protein

rev, 151-159 tat, 151, 159

antibody, 290, 299, 303 and AIDS, 105, 109-114, 135,

145 and blood transfusion, multi­

ple, 299 in Buffalo green monkey cell

culture, 305 carrier, 125, 146 core antigen p-24, 303 diseases, 106 ELISA, 301 enzyme immunoassay, 290 expression, regulation of,

151-159 and hepatitis B virus, 311 in homosexuals, 25 immunofluorescence assay, 290 incubation time, 125-127 infection

diseases, 106 models, 135

laboratory quality assurance program, 290

latency, 125, 135 LTR promoter sequence, 135,

146, 151-159, 304, 311 neuropathology, 105 in oncology patient, pedia-

tric, 299 prevalence, 125 protein, 151-159 provirus, 135, 145 replication inhibition, 304-

305 mRNA, 151-159, 304 in semen, 124 susceptibility, 133 syphilis, coexisting, 301

Immunodeficiency virus, human, type-1 (continued) tat (transactivator) protein,

151-159 transactivation

by herpes simplex virus 135-149

transmission, 122-124 type-2, 109 Western blot, 290, 301

Immunodeficiency virus, human type-2, 109

Immunofluorescence method, 28-31, 151, 153, 277, 286, 310

Immunogen, 225, 229 Immunoglobulin

IgA, 227, 229, 236 IgG, 310 IgM, 280

Immunomodulator, 254 Immunopathology, virus-induced,

191-192 Immunoperoxidase, 4-6, 9, 273 Immunoprecipitation, 54, 196 Immunosuppression in patient

and rhinovirus, 213 Infection, bacterial, enteric,

191 Infection, viral, see separate

viruses Infectious mononucleosis, 88, 92,

95, 103 Influenza, 192, 257 Influenza virus, 240, 248-250,

286, 288 RNA polymerase, 249, 258

Interferon, 192, 200, 211 alpha, 81, 144, 149, 236, 304 beta, 137, 138, 149, 164, 166,

170, 190, 240, 243, 246, 254, 297

gamma, 149, 166 Interleukin

-1, 256 -2, 26, 27, 152, 254, 256, 313 -3, 254

Isoniazid, 112

Kaposi's sarcoma, 110 Keratitis, 307, see Herpes Keratoconjunctivitis, epidemic

and adenovirus, 185 Key hole limpet hemocyanin, 215 Killer cell, natural (NK cell),

164-169, 176, 189, 190, 209, 243, 313

Koch-Evans postulates, 88

Latex agglutination test, 4, 7, 281

Lavage, bronchoalveolar, 111 LCMV, choriomeningitis virus,

lymphocytic Lectin, 170 Leukemia

hairy cell, 26, 30, 108

Leukemia (continued) lymphoid, of adults, see T-cell

myeloblastic, 95 Leukocyte, polymorphonuclear, 243 Leukoprotein-B~, 175 Leukotriene, 175 Levamisole, 81, 163 Lipofuscin, 13 Lipopolysaccharide, bacterial,

303 Liposome, 250, 257

adjuvant for peptide antigen, 230

Liver disease, 78-80 Liver transplantation, 96, 103 Long terminal repeat, see LTR LTR promoter sequence in cell

line, 135-146, 304 Luciferase, 152, 311 Lung cell, human, fetal, 283 Lupus erythematosus, systemic, 30 Lymphadenopathy, 24 Lymphocyte, 74, 88, 90, 92, 94,

98, 103, 188 granular in lymphoprolifera­

tive disease, 30 transformed by virus, 74 see B-cell, T-cell

Lymphocytic choriomeningitis virus, see Chorio­meningitis

Lymphokine, 190, 239, 240, 247, 254, 256

Lymphoma and virus, 109 Lymphoproliferative disease, 30 Lysis, cellular, 189

see Cytolysis

Macrophage, 103, 155, 167-172, 175, 190, 192, 199, 243, 297, 313

-granulocyte stimulating factor, 220

Malaria vaccine, 265-266 Measles, 113, 192, 239 Membrane, cytoplasmic fluores-

cence test, 28-31 Meningitis, syphilitic, 120 Meningoencephalitis, viral, 3,

185 Methotrexate, 309 MHC, see histocompatibility

complex, major, 190 Microglobulin, 190 Microneutralization test, 217 Microtubule, 187 Migration-inhibition factor, 175 Mink lung cell, 273 Moloney's leukemia virus, 251 Monkey kidney cells, 153, 193 Monocyte, 155, 226, 298 Mononucleosis, infectious, 88,

92, 95, 103, 284 Monospot test, 284 Mouse, 161-182

immunocompromised, 313 myocarditis, see Myocarditis,

murine

327

Mouse (continued) strain, 164, 244, 189, 295, 313 Multiple sclerosis, 30 Murabutide, 230 Muramyl dipeptide, 254 Mycobacterium tuberculosis, 110,

112, 254, 257 strain BCG, 254 M. avium complex, 111

Mycoplasma hominis, 275 Myelopathy, 309

HTLV-I associated, 24, 108 Myocarditis, murine

acute, 161-182 coxsackie virus-induced,

161-182 mechanism proposed, 173-176

Myocardium cells for virus replication,

168-170 virus-induced pro-inflammatory

events, 170-173 Myocyte, 161, 164, 165

necrotic, 164, 165 Myosin, 180

antibody, monoclonal, 300 cardiac, murine, 162

Natural killer cell (NK), see Killer cell, natural

Necrosis factor, 243 Neuraminidase of influenza A

virus, 249 Neutralization assay, 297 Non A-non B hepatitis virus, 73,

80, 84 in chimpanzee, 80

Oncogene, 189 anti -, 189

Oncology patient, pediatric and HIV-1 infection, 299

Organ transplant patient and cytomegalovirus, 300

Ovalbumin, 226 Ox cell hemolysin test, 284

Parainfluenza virus, 286 vaccine, 236

Paraparesis, spastic, 309 tropical, 24, 108

and HTLV-I, 24 Parvovirus Bl9, 289

disease, 289 Pentamidine, 111 Peptide, synthetic, 224-229

for human use, listed, 225 as rhinovirus vaccine, 224-227

Pertusis-like syndrome, 185 and adenovirus, 185

Pharyngitis, febrile, 185 and adenovirus, 185

Phosphonoacetic acid, 137 Phosphonoformate, 112, 306 Picornaviridae, see Coxsackie

virus Plasmid, 283, 309 Plasminogen activator, 152

328

Pneumocystis car2n22 pneumonia 110, 111

Pneumonia and adenovirus, 185 and Pneumocystis, 110, 111

Poliovirus type-1, 163, 218, 219, 226

serotypes, 215 structure, 214

Polyadenylation, 194, 198 Polyathralgia, 289

and parvovirus, 289 Potato virus X, 312 Precipitation, radioimmune, 29 Prednisolone phosphate, 307 Pregnancy and viruses, 47-49,

289, 302 Propidium iodide, 308 Prostacyclin, 172, 174 Prostitution, 302 Prostaglandins, 171-175 Protein derivative, purified

of Mycobacterium tuberculosis, 254, 257

Protein, viral, see separate viruses

Rabbit herpes keratitis, 307 kidney cell culture of herpes

simplex virus, 10-12, 15 vaccination, intranasal, 227-

230 Radioimmunoassay (RIA), 28, 29,

54, 61, 289, 297 Radioimmunoprecipitation, 295 RAMP culture confirmation test,

271, 272 Reiter's syndrome, 191, 212 Respiratory disease, acute

and adenovirus, 185 Respiratory syncytial virus 192,

220, 249, 286, 287 detection, 287

Restriction endonuclease, 275 fragment analysis, 93, 98, 100

Restriction enzyme BamHI, 283 Reticulum, endoplasmic, 193, 195,

251, 257 Retinoblastoma, 189 Retrovirus, human, 23, 105-120,

249, 298 antigen gag, 249 infections by, 105-120 isolation in 1978, 23 in T-cell malignancy, see T­

cell lymphotropic virus transmission, mode of, 105

Rev responsive element (RRE) protein, 154

Reverse transcriptase, 105, 298 Rhabdomyosarcoma cells, 288 Rhesus monkey kidney cells, 288

hemadsorption, 288 Rheumatoid arthritis, see

Arthritis, rheumatoid Rhinovirus, 213-238

amino acid sequence of pep­tides, 216

animal model for, 288-230

Rhinovirus (continued) antibody, 214-224, 230

Canyon hypothesis, 214-219 against peptide, see anti­

peptide antigen drift, 214 antipeptide antibody, 215-225,

230 in microneutralization test,

217-218 Canyon hypothesis of struc-

ture, 214-219 capsid protein, 220 in chimpanzee, 230 in cold, common, 213 crystallography by x-ray, 214 drift, antigenic, 214 in HeLa cell, 219 and IgA secretory response,

227 microneutralization test, 217-

218 model for, 228-230 peptide

amino acid sequence, 216 antibody against, 215-224,

230 synthetic, 213-238

in rabbit, 228-229 and receptor binding site,

213-238 serotypes, human, 213-214 structure, 214-219 see Canyon

hypothesis surveillance, immune, 214 type-2, 215 type-14, 214 type-89, 217 vaccine, 213-238 x-ray crystallography, 214

Rickettsia, 199 RIP-PAGE, 31,34 RNA

messanger -, 194, 304 TATAA box, 194

polymerase, 85, 169, 249, 258 probe, biotinylated, 283

Rubella syndrome, congenital, 191

Salivary gland cell, 313 Sclerosis, multiple, 30

and HTLV-I antibody, 30 Sendai virus, 191, 248, 250 Shell vial centrifugation culture

method, 270-273, 277, 278, 287, 288, 306

Shigella sp., 114 Simian virus-40 (SV40), 136, 149,

191, 193, 240, 249, 251, 255

"Smudge" cell, 188 Southern blotting, 27 Soybean lectin, 170 Spleen cell, 313 Splenocyte, immune, 244 Sperm whale myoglobin, 226 Spondylarthropathy, 191 Staphylococcus A-sepharose

column, 43

Steroid therapy, 81 Stimulation index, defined, 62 Streptococcus pneumoniae, 110 SV40, see Siminan virus-40 Syphilis, 113,114, 120, 129, 301-

302. Tat (transactivator) 142-143

gene, 149 protein, 151-159

Tax gene, 25-26, 294-295 T-cell, 27, 53, 106, 155, 161,

163, 167-171, 192, 226, 227, 229, 231, 254

Cytotoxic, 163, 166-168, 189-193, 208, 210, 237, 244-247

activation, 247-254 antiviral, 239-266 immunity, cellular, 55-63 induction, 246-247 response to vaccine, 256-

260 suppression, 255-256

helper cell, 109, 167, 168, 190, 231, 237, 254, 255, 256

immunity, cellular, 55-63 and interleukin-2, 259 and leukemia, adult (ATL), 23,

24, 38, 108, 309 and lymphoma, 108 suppressor, 255-257 virus-infected, 23, 27-29

T-cell lymphotropic virus, human, type-! (HTLV-I), 23-39, 105

antibody, 23, 30-34 antigen, 27 by blood transfusion, 25, lOB,

109 in breast milk, 25 carrier, 26 disease, 24 distribution, geographic, 23 in drug abuser, intravenous,

109 DNA proviral, 24 electron microscopy, 27 envelope protein, 291, 309 gene

product in E. coli, 291-293 tax, 25-26

glycoprotein gp46, 291 in hairy cell leukemia, 26 and interleukin-2, 26 isolation, 27 laboratory tests for, 23-39 in leukemia, hairy cell -, 26 LTR promoter sequence, 135 in lymphoma, 109 in monkey, 23 and nucleic acid hybridiza­

tion, 27 and polymerase chain reaction,

27 protein, 26, 30-34, 291, 292,

294 of envelope, 291 membrane-bound, 291

329

T-cell lymphotropic virus, human type-! (continued)

precursor - gag p55, 292 of tax gene in E. coli, 294-

295 for transactivation/trans-

cription, 294 reverse transcriptase, 27 tests, 23-39 transcription/transactivation

protein, 294 transmission

sexual, 25, 108 vertical, 25-26, 108

by transfusion, see blood transfusion

Tetanus toxoid, 229 Tissue plasminogen activator, 152 T-lymphocyte, see T-cell TNF, 199, 200, 184 Tonsilitis

and adenovirus, 185 Toxoplasma gondii, 110, 113 Toxoplasmosis, 113 Transactivation, 153

bioasay, 155-157 viral, 135-149

Transactivator protein tat, 151-153

Transformation by DNA virus, 188-189

Transfusion, see Blood transfu­sion

Transcription inhibitor, see Actinomycin D

Translation inhibitor, see Cyclohexamide

Transplant patient, cardiac, 280 and adenovirus, 186

Transplant patient, hepatic, 96, 103

Trimethoprim-sulfamethoxasole, 111

Tube culture of virus, 270, 277, 279 see Shell vial culture

Tuberculin test, 112 Tuberculosis, 113 see Mycobac-

terium tuberculosis Tumor necrosis factor, see TNF Tunicamycin, 248, 310 Turbinate cell, bovine, 308

Ulcer disease, genital, 114 see Chancroid, Herpes,

Syphilis Ulex europaeus agglutinin I, 170,

171 Ultraviolet irradiation, 146, 148 Ureaplasma urealyticum, 275

Vaccinia recombinant virus, 241, 248-251, 255, 258, 259

hemagglutinin, 259 vaccine, 246

Vaccine

330

criteria for, 224 peptides for human use

listed, 225

Varicella-zoster virus, 41-71, 286 antibody, 52 ELISA for, 53-56 monoclonal, 53, 60 neutralizing, 61, 62 antigen, 54 congenital, 52 cytotoxicity, cellular, 52 DNA probe, biotinylated, 283 ELISA, 53-56 genome, 283 in guinea pig, 60-63 immunity, 52-63

cellular,53, 54, 57, 60 and proteins, 41-42, 52-63 and T-cell proliferation,

55-63 y-interferon, 54, 57-60 in population groups, 52

52-63 protein and immunity, 41-42, 52-

63 radioimmunoassay (RIA), 54 RNA probe, biotinylated, 283 stimulation index, 62 strain Caque, 283 vaccine, attenuated, 52, 55,

57-60 Vesicle, endocytic, 189 Vesicular stomatitis virus, 248

G protein, 248 Vimenten, 180 Viroid of plant, 74, 85

and hepatitis delta virus, 85 Virus

activator protein, 151 clearance in mouse, 297 immune response, 189-200 infection and immune response

189-200 latency, 192, 193 persistence, 192, 193 see separate viruses

Viruses adenovirus, 183-121, 275, 285-

286 arenavirus, 255 chicken embryo lethal orphan

virus, 202 choriomeningitis· lymphocytic

virus, 192, 240, 255, 258, 259

coxsackie virus, 161-182, 191, 286

cucumber mosaic virus, 74 cytomegalovirus, 111-112, 136,

146, 245, 249, 277-282 dengue fever virus, 192 echovirus, 218, 286 ectromelia poxvirus, 255 enterovirus, 275 Epstein-Barr virus, 87-104,

284 foot-and-mouth disease virus,

215, 226, 229

Viruses (continued) hepatitis virus

B, 73-77, 80, 85, 86, 125, 132, 185, 201, 209, 241, 311

delta, 73-86 nonA-nonB, 73, 80, 84

herpes simplex virus, 1-21, 41-71, 104, 110, 135-149, 185, 239-245, 248, 249, 255, 257, 259, 270-276, 285, 286, 297, 307-310

Immunodeficiency virus, 24, 25, 105-110, 121-159, 192, 259, 290, 299, 301, 304' 305' 311

influenza vi~us, 240, 248-250, 258, 286, 288

Moloney's leukemia virus, 251 parainfluenza virus, 236, 286 parvovirus, 289 picornavirus, 214 poliovirus, 163, 214, 215,

218, 219, 226 potatovirus X, 312 rhinovirus, 213-238 respiratory syncytial virus,

192, 220, 249, 286, 287 retrovirus, 23, 105-120, 249,

298 rubella virus, 191 Sendai virus, 191, 248, 250 simian virus-40, 136, 149,

191, 193, 240, 249, 251, 255

T-ce1l lymphotropic virus, 23-39, 105, 108, 109, 135, 291-295, 309

varicella-zoster virus, 41-71, 283, 286

woodchuck hepatitis virus, 85 Virusoid, see Viroid

Western blot analysis, 29-34, 39, 42, 98, 280, 290, 295, 299, 309, 310

see Immunoblot Woodchuck hepatitis virus, 85

X-ray crystallography of picornavirus, 214

Zidovudine (azidothymidine, AZT), 106

331